Plus   Neg

Altimmune Submits IND Application For AdCOVID Intranasal COVID-19 Vaccine - Quick Facts

Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, said Wednesday that it has submitted an Investigational New Drug or IND application to the U.S. Food and Drug Administration (FDA) to commence a Phase 1 clinical study of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.

AdCOVID is designed to stimulate a broad immune response including both systemic immunity (neutralizing antibody) and local immunity (mucosal IgA and resident memory T cells) in the nasal cavity and respiratory tract.

Altimmune noted that the single-dose nasal spray offers greater ease and comfort of administration and positions AdCOVID as a differentiated vaccine candidate for adults and children.

According to the company, AdCOVID is capable of stimulating an additional and specialized type of immunity, local nasal mucosal immunity, that is believed to be critical for preventing further transmission of the virus.

"We've made exceptional progress advancing AdCOVID and are on track to begin a Phase 1 clinical study this year, with a data readout anticipated in the first quarter of 2021. While the progress being reported with current vaccines is very encouraging, many in the scientific and medical communities agree that there is continued need for next-generation vaccines that offer significant enhancements," said Vipin Garg, President and Chief Executive Officer of Altimmune.

Altimmune noted that the FDA, in a recent pre-IND meeting, agreed to the overall Phase 1 study design and patient population, as well as plans for manufacturing and product testing of AdCOVID.

Further, the FDA confirmed that additional nonclinical studies were not required and that the toxicology data previously submitted and reviewed for Altimmune's NasoShield and NasoVAX intranasal vaccine candidates support the clinical development of AdCOVID.

No additional toxicology studies are required before the start of the Phase 1 trial.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Electric Co. filed a lawsuit against Siemens Energy AG, accusing the German power distribution company of stealing trade secrets for gas turbines. Siemens Energy allegedly used the information to get at least nine contracts to supply gas turbines to public utilities, and also covered up improper business gains. Following a court ruling, the U.S. Food and Drug Administration postponed the effective date for tobacco manufacturing companies to display new health warnings on cigarette packets and in advertisements, by additional 90 days. The warnings with color images is to promote greater public understanding of the negative health consequences of smoking. JPMorgan Chase & Co (JPM) reported strong results in the fourth quarter of 2020, with net profit up 42% largely driven by credit reserve releases of $2.9 billion. The Group said it ended the year with a CET1 ratio of 13.1% and capital above $200 billion, providing with meaningful capacity to further...
Follow RTT